Last reviewed · How we verify
NCT04148092
Expanded Access Program of Ripretinib (DCC-2618) for the Treatment of Patients With Advanced GIST
trial testing ripretinib in GIST - Gastrointestinal Stromal Tumor. Approved for marketing.
Quick facts
| Lead sponsor | Deciphera Pharmaceuticals, LLC |
|---|---|
| Status | APPROVED FOR MARKETING |
| Study type | EXPANDED_ACCESS |
Drugs / interventions tested
- ripretinib — full drug profile →
Conditions studied
- GIST - Gastrointestinal Stromal Tumor — all drugs for GIST - Gastrointestinal Stromal Tumor →
Sponsor
Deciphera Pharmaceuticals, LLC — full company profile →
Who can join
18 and older, any sex, with GIST - Gastrointestinal Stromal Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open-label, single-arm, multicenter expanded access study to provide patients who have locally advanced unresectable or metastatic gastrointestinal stromal tumor (GIST) and have received treatment with at least 2 prior Food and Drug Administration (FDA)-approved therapies early access to ripretinib until such time that ripretinib becomes commercially available or the Sponsor chooses to discontinue the program.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Ripretinib: First Approval.
Dhillon S. · · 2020 · cited 52× · PMID 32578014 · DOI 10.1007/s40265-020-01348-2 -
Preclinical model-based evaluation of Imatinib resistance induced by <i>KIT</i> mutations and its overcoming strategies in gastrointestinal stromal tumor (GIST).
Zhao Q, Zhang C, Qi C, Yang J, et al · · 2021 · cited 6× · PMID 35035701 -
Efficacy and Safety of Ripretinib in Advanced Gastrointestinal Stromal Tumors within an Expanded Access Program: A Cohort Study.
Lim SY, Ferro-López L, Barquin E, Lindsay D, et al · · 2024 · cited 2× · PMID 38473346 · DOI 10.3390/cancers16050985 -
Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter?
Thirasastr P, Sutton TL, Joseph CP, Lin H, et al · · 2024 · PMID 38473266 · DOI 10.3390/cancers16050904
Verify or expand the search:
- PubMed search for NCT04148092
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Deciphera Pharmaceuticals, LLC trials
Trials by the same sponsor.
- NCT07158411 — Evaluate the Effect of Vimseltinib on Organic Cation Transporter 2 (OCT2) · Phase 1 · completed
- NCT07158398 — Evaluate the Effect of Vimseltinib on the Pharmacokinetics of a BCRP and OATP1B1 Substrate · Phase 1 · completed
- NCT06287463 — Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathw · Phase 1 · terminated
- NCT04530981 — A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate i · Phase 1 · completed
- NCT04892017 — Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors · Phase 1 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04148092 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Deciphera Pharmaceuticals, LLC
- Last refreshed: 29 May 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04148092.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing